Biren Amin
Stock Analyst at Piper Sandler
(3.21)
# 1,074
Out of 5,140 analysts
67
Total ratings
45.61%
Success rate
4.06%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $5.65 | +183.19% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $3.57 | +96.08% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $24.54 | +95.60% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $18.59 | -13.93% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $70.72 | +38.57% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $12.05 | +456.02% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $7.03 | +340.97% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $54.43 | +74.54% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $3.23 | +85.76% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $2.32 | +72.41% | 1 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $5.88 | +189.12% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.13 | +228.64% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $24.96 | +52.24% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $6.39 | +87.79% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $31.10 | +128.30% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.68 | +355.73% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $22.14 | -5.15% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $66.53 | +72.85% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $22.80 | +40.35% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.21 | -6.54% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.52 | +2,677.78% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.16 | +30,940.78% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.08 | +372.44% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.79 | +609.81% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.40 | +123,601.14% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.30 | +35.92% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $782.38 | -11.68% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $5.47 | +82.82% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $55.46 | +82.11% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $130.10 | -46.96% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $469.27 | -66.97% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $6.34 | +2,045.11% | 4 | Mar 6, 2017 |
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $5.65
Upside: +183.19%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $3.57
Upside: +96.08%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $24.54
Upside: +95.60%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $18.59
Upside: -13.93%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $70.72
Upside: +38.57%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $12.05
Upside: +456.02%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $7.03
Upside: +340.97%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $54.43
Upside: +74.54%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.23
Upside: +85.76%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $2.32
Upside: +72.41%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.88
Upside: +189.12%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $2.13
Upside: +228.64%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $24.96
Upside: +52.24%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $6.39
Upside: +87.79%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $31.10
Upside: +128.30%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $7.68
Upside: +355.73%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $22.14
Upside: -5.15%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $66.53
Upside: +72.85%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $22.80
Upside: +40.35%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.21
Upside: -6.54%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.52
Upside: +2,677.78%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.16
Upside: +30,940.78%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.08
Upside: +372.44%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.79
Upside: +609.81%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.40
Upside: +123,601.14%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $10.30
Upside: +35.92%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $782.38
Upside: -11.68%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $5.47
Upside: +82.82%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $55.46
Upside: +82.11%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $130.10
Upside: -46.96%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $469.27
Upside: -66.97%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $6.34
Upside: +2,045.11%